XML 30 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue
9 Months Ended
Sep. 30, 2024
Revenue  
Revenue

Note 11. Revenue

We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product line:

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In thousands)

    

2024

2023

2024

2023

Revenue

Lymphedema products

$

65,282

$

62,506

$

182,278

$

172,257

Airway clearance products

7,811

7,080

25,121

24,514

Total

$

73,093

$

69,586

$

207,399

$

196,771

Percentage of total revenue

Lymphedema products

 

89%

 

90%

 

88%

 

88%

Airway clearance products

11%

10%

12%

12%

Total

 

100%

 

100%

 

100%

 

100%

Our revenue by channel, inclusive of sales and rental revenue, for the three and nine months ended September 30, 2024 and 2023, are summarized in the following table:

Three Months Ended

Nine Months Ended

September 30,

September 30,

(In thousands)

    

2024

2023

2024

2023

Private insurers and other payers

$

47,564

$

39,376

$

122,907

$

101,300

Veterans Administration

8,442

7,259

23,339

20,203

Medicare

9,276

15,871

36,032

50,754

Durable medical equipment distributors

7,811

7,080

25,121

24,514

Total

$

73,093

$

69,586

$

207,399

$

196,771

Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component.

The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Condensed Consolidated Balance Sheets. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by third-party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third-party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable.

Rental revenue for the three and nine months ended September 30, 2024 and 2023, was primarily from private insurers. Sales-type lease revenue and the associated cost of revenue for the three and nine months ended September 30, 2024 and 2023, was:

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2024

2023

2024

2023

Sales-type lease revenue

$

9,925

$

10,720

$

26,657

$

25,312

Cost of sales-type lease revenue

 

2,703

 

3,211

 

8,270

 

9,122

Gross profit

$

7,222

$

7,509

$

18,387

$

16,190